Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) has been given an average rating of “Moderate Buy” by the eight analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $38.71.
A number of research firms have weighed in on SGRY. Royal Bank of Canada decreased their target price on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. KeyCorp assumed coverage on shares of Surgery Partners in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. UBS Group initiated coverage on shares of Surgery Partners in a research report on Monday, October 14th. They issued a “buy” rating and a $38.00 price target for the company. Macquarie reiterated an “outperform” rating and set a $34.00 price target on shares of Surgery Partners in a research note on Tuesday, November 19th. Finally, StockNews.com lowered shares of Surgery Partners from a “hold” rating to a “sell” rating in a research note on Wednesday, August 7th.
Check Out Our Latest Report on Surgery Partners
Institutional Inflows and Outflows
Surgery Partners Trading Up 1.7 %
Shares of NASDAQ SGRY opened at $23.39 on Tuesday. The stock has a fifty day simple moving average of $29.86 and a 200-day simple moving average of $28.36. Surgery Partners has a twelve month low of $21.36 and a twelve month high of $36.92. The stock has a market capitalization of $2.97 billion, a PE ratio of -49.27, a PEG ratio of 19.15 and a beta of 2.76. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.06). Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The firm had revenue of $770.40 million for the quarter, compared to analysts’ expectations of $768.99 million. During the same quarter in the previous year, the company posted $0.15 earnings per share. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. On average, equities analysts forecast that Surgery Partners will post 0.73 earnings per share for the current year.
About Surgery Partners
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Further Reading
- Five stocks we like better than Surgery Partners
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- What Are Some of the Best Large-Cap Stocks to Buy?
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.